A Study to Investigate the Safety and Efficacy of Ricolinostat

Peripheral Nervous System Diseases Clinical Trial

Official title:

An Exploratory Study to Investigate the Safety and Efficacy of Ricolinostat for Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05229042
• Other study ID #: BCRG-CN-101
• Status: Completed
• Phase: Phase 1
• Start date: January 1, 2022
• Est. completion date: November 10, 2023

Study information

• Verified date: March 2023
• Source: Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.

Description:

This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.

Prior to randomization, patients will participate in the Screening and Baseline assessment period to ensure that they meet study inclusion/exclusion criteria.

Following the Screening and Baseline assessment period, patients who meet entry criteria will be randomized in a 2:1 ratio to receive either ricolinostat or placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 10, 2023
• Est. primary completion date: November 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Able to understand the study's purpose and requirements, and able to voluntarily provide informed consent to participate.

2. Age = 18 years and < 70 years at the time of signing the informed consent form (ICF).

3. Female patients diagnosed with breast cancer:

1. Who have been treated with either docetaxel or paclitaxel.

2. Who have a Karnofsky performance status of 70 or more at Screening.

3. Who have completed their chemotherapy at least 1 month prior to randomization.

4. Neuropathy of <Grade 4 using the general guideline of grading scales defined in Common Terminology Criteria for Adverse Events (CTCAE; v5.0) .

5. Women of childbearing potential (WOCBP) must agree to use reliable contraceptive methods for the duration of the study and for at least 3 months after completing treatment with study drug. For the purposes of this study, reliable methods of contraception include abstinence, oral contraceptives, hormonal contraceptive implants such as Nexplanon, hormonal vaginal ring such as NuvaRing, intrauterine devices in place for at least 3 months, or barrier methods used in conjunction with spermicide. To be considered post-menopausal and of non childbearing potential, women less than 60 years with less than 2 years since their last period must have follicle-stimulating hormone (FSH) > 40 IU/L and estradiol < 20 pg/mL unless on hormone replacement.

6. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Women who are pregnant or lactating.

2. Extremely overweight, defined as body mass index (BMI) > 40 kg/m2.

3. Presence of any neuropathy other than CIPN.

4. Presence of a clinical condition commonly associated with neuropathy that could better account for the presence of the patient's neuropathy, such as diabetes or a risk factor for marked B12 deficiency (malabsorption syndrome, atrophic gastritis, strict vegan diet, etc.), or a megaloblastic (macrocytic) anemia consistent with B12 deficiency.

5. Presence of skin conditions in the affected dermatome that, in the judgement of the Investigator, could interfere with evaluation of the neuropathic pain condition.

6. Presence of non-CIPN pain that may interfere with study assessments and/or self-evaluation of peripheral neuropathic pain.

7. History of alcoholism or drug/chemical abuse within 1 year prior to randomization as judged by the Investigator based on clinical history.

8. Opioid use at a dose of = 30 morphine milligram equivalents on 3 or more days a week during the month at Screening.

9. The use of cannabidiol (CBD) during the 1 month at Screening.

Related Conditions & MeSH terms

• Nervous System Diseases
• Peripheral Nervous System Diseases

Intervention

Drug:
• Ricolinostat
Oral

Locations

Country	Name	City	State
China	Beijing3ERegenacy	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TEAT	The primary endpoint is the incidence of treatment-emergent adverse events (TEAEs) during the Treatment period.	6 months